Chimeric antigen receptor (CAR)-T cell therapy has emerged as one of the most groundbreaking advances in modern medicine, heralding a new era in the treatment of hematological malignancies. By genetically engineering a patient’s own T cells to express CARs that target specific antigens on cancer cells, this therapy has unlocked unprecedented potential for precision immunotherapy. However, despite its remarkable successes, CAR-T cell therapy is not a universal panacea. Several intrinsic limitations stemming from the biology of conventional T cells, as well as challenges in manufacturing and clinical deployment, restrain its efficacy and broad applicability. Recent explorations into alternative immune cell types for CAR engineering hold promise for surmounting these challenges, potentially revolutionizing immunotherapy beyond the current paradigm.
Conventional T cells, while highly potent effector cells in immune surveillance and destruction of malignant cells, exhibit inherent functional constraints that impact CAR-T therapy outcomes. Factors such as exhaustion after repeated antigen stimulation, limited persistence, and the immunosuppressive tumor microenvironment dampen their sustained anti-tumor activity. Moreover, limitations in trafficking to tumor sites, issues with cytokine release syndrome, and the risk of graft-versus-host disease in allogeneic CAR-T treatments add further complexity. The manufacturing process itself, which typically involves autologous T cell collection, genetic modification, and expansion, is time-consuming, costly, and often results in products with variable quality and efficacy.
In response to these challenges, scientific efforts have increasingly turned towards harnessing the unique properties of immune cells beyond conventional αβ T cells. This strategy, broadly designated as “CAR-X” cell engineering, leverages the diverse biology of alternative immune populations such as natural killer (NK) cells, invariant natural killer T (iNKT) cells, γδ T cells, and macrophages. Each of these cell types possesses distinct functional attributes that may complement or surpass the capabilities of traditional CAR-T cells. Consequently, CAR-X therapies promise to enhance clinical efficacy, reduce side effects, and enable applications across a broader spectrum of diseases including solid tumors, infectious diseases, and autoimmune disorders.
Natural killer cells, for instance, play a vital role in innate immunity through their ability to recognize and eliminate virally infected or transformed cells without prior sensitization. Their intrinsic cytotoxicity and cytokine secretion profiles endow them with rapid effector functions. Notably, NK cells display a reduced risk of causing graft-versus-host disease, making them attractive candidates for allogeneic “off-the-shelf” CAR therapies. However, the limited in vivo persistence and challenges in genetic modification have historically hindered their development. Advances in gene editing and culture conditions are addressing these issues, enabling the generation of CAR-NK products with improved longevity and potent tumor-killing capacities.
Invariant natural killer T cells combine features of both innate and adaptive immunity with their semi-invariant T cell receptors recognizing glycolipid antigens presented by CD1d molecules. This unique biology allows iNKT cells to modulate the immune microenvironment profoundly, not only attacking tumor cells directly but also stimulating other immune effectors and overcoming immunosuppression. Engineering CARs into iNKT cells leverages these dual functionalities, offering a multifaceted therapeutic approach. Furthermore, iNKT cells exhibit lower alloreactivity, suggesting a safer profile for allogenic therapies.
Similarly, γδ T cells represent a distinct T cell lineage characterized by their γδ T cell receptors, which recognize stress-induced ligands independent of major histocompatibility complex (MHC) presentation. This property confers several advantages, including broad tumor recognition and the ability to function in an immunosuppressive milieu. CAR-γδ T cells can exploit these features to target cancers resistant to conventional therapies while benefiting from innate-like recognition pathways that limit immune escape. Ongoing innovations in ex vivo expansion and genetic engineering techniques are enabling scalable production of CAR-γδ T cell products.
Macrophages, traditionally viewed as phagocytic cells involved in tissue homeostasis and inflammation, are emerging as compelling vectors for CAR therapy due to their natural tumor infiltration and antigen-presenting capabilities. CAR-macrophages can potentially engulf and destroy tumor cells directly and orchestrate robust antitumor immune responses by activating adaptive immunity. Moreover, they can be engineered to remodel the tumor microenvironment, counteracting immune evasion mechanisms. Despite technical challenges in genetic modification and expansion, recent breakthroughs in viral and non-viral transduction methodologies have propelled CAR-macrophage development forward.
The design of CAR constructs tailored specifically to each immune cell type is another critical frontier in CAR-X engineering. Conventional CARs optimized for αβ T cells may not fully harness the unique signaling pathways and functional mechanisms of alternative immune cells. For example, CARs in NK cells often incorporate signaling domains derived from activating NK receptors like NKG2D or DAP12 to promote-specific activation, while CARs for macrophages integrate phagocytosis-inducing domains. Fine-tuning CAR architecture to synergize with endogenous signaling can substantially enhance efficacy and persistence within the host.
Manufacturing platforms are also evolving to accommodate the cell-specific requirements of CAR-X therapies. Whereas CAR-T cell production typically relies on lentiviral or retroviral transduction of T cells collected via leukapheresis, alternative approaches such as non-viral gene editing, mRNA electroporation, and stem cell differentiation protocols are being adapted. These tailored manufacturing strategies aim to improve scalability, safety profiles, and the timely generation of clinical-grade CAR-X products. Additionally, the potential to create universal donor cell banks using gene editing to prevent rejection or graft-versus-host disease presents a paradigm shift toward ready-to-use allogeneic cell therapies.
From a clinical perspective, early-phase trials integrating CAR-NK, CAR-iNKT, and CAR-γδ T cells have demonstrated encouraging safety profiles and preliminary efficacy signals, particularly in refractory hematological malignancies. The intrinsic biology of these cells contributes to attenuated cytokine release syndromes and neurotoxicity, which are common adverse events in CAR-T therapy. Moreover, solid tumor targeting, a notorious hurdle for CAR-T cells, may be more achievable with CAR-X cells due to their distinct trafficking and tissue-infiltrating capabilities. Accordingly, the clinical landscape is rapidly expanding, encompassing hematologic cancers, solid malignancies, viral infections, and even fibrotic or autoimmune diseases.
Despite these exciting developments, significant challenges remain in translating CAR-X technologies into widely available therapies. The heterogeneity of alternative immune cells necessitates optimization in expansion, persistence, and potency to achieve consistent therapeutic responses. Immune evasion by tumors, antigen heterogeneity, and immune suppression continue to pose obstacles that demand combinatorial or multifunctional engineering strategies. Concurrently, regulatory frameworks must adapt to the complexity of these novel therapies to ensure safety without stifling innovation.
In summary, CAR-X cell engineering represents a transformative frontier in immunotherapy, leveraging the diversity of the immune system to overcome the constraints of conventional CAR-T approaches. By harnessing the unique effector mechanisms and biological properties of NK cells, iNKT cells, γδ T cells, macrophages, and potentially other immune subsets, this paradigm expansion is poised to unlock new avenues for treating cancer and beyond. The iterative refinement of cell-specific CAR designs, manufacturing methods, and clinical applications heralds a future where personalized, effective, and safer cellular therapies redefine medicine.
As research accelerates, collaborations between academic institutions, biotechnology companies, and regulatory agencies will be paramount in propelling CAR-X therapies from experimental stages to mainstream clinical use. Integrative efforts that combine multi-omic profiling, machine learning, and synthetic biology will undoubtedly yield next-generation CAR constructs and cell products with enhanced functionality. In concert, ongoing clinical trials will illuminate the therapeutic landscape, refining indications, dosing regimens, and combination approaches to optimize patient outcomes.
Ultimately, the story of CAR-X cell engineering is one of innovation driven by the limitations of prior successes, a testament to the relentless pursuit of harnessing the immune system’s vast potential. The next decade promises to be pivotal, with the envisioned convergence of diverse immune cell engineering shaping a new chapter in immunotherapy that extends hope to millions of patients worldwide.
Subject of Research: Development and application of alternative immune cells engineered with chimeric antigen receptors (CAR-X) for enhanced immunotherapy.
Article Title: CAR-X cell engineering.
Article References:
Li, X., Lin, H., Liang, J. et al. CAR-X cell engineering. Nat Rev Bioeng (2026). https://doi.org/10.1038/s44222-026-00430-w
Tags: allogeneic CAR-T therapy risksalternative immune cell CAR engineeringCAR T cell therapy advancementschallenges in CAR-T manufacturingchimeric antigen receptor engineeringcytokine release syndrome managementhematological malignancies treatmentimmune cell exhaustion in cancer therapylimitations of conventional T cellsnext-generation immunotherapy approachesovercoming tumor microenvironment suppressionprecision cancer immunotherapy
